Pharmaceutical giant Pfizer plans to cancel its diabetes drug Exubera. The company expected the drug to become a blockbuster, but prescriptions are still less than 1 percent of the insulin market. That makes Exubera one of the most expensive miscalculations in the pharmaceutical industry's history. The failure will cost Pfizer $2.8 billion. It said overall profit plunged 72 percent.
Pfizer to Pull Exubera as Profits Plunge
News & Features National Public Radio · NPR ·